WO2011087765A3 - Methods of producing stabilized solid pharmaceutical compositions containing morphinans - Google Patents
Methods of producing stabilized solid pharmaceutical compositions containing morphinans Download PDFInfo
- Publication number
- WO2011087765A3 WO2011087765A3 PCT/US2010/061400 US2010061400W WO2011087765A3 WO 2011087765 A3 WO2011087765 A3 WO 2011087765A3 US 2010061400 W US2010061400 W US 2010061400W WO 2011087765 A3 WO2011087765 A3 WO 2011087765A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- pharmaceutical compositions
- compositions containing
- solid pharmaceutical
- producing stabilized
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Abstract
Methods for producing stabilized solid dosage form pharmaceutical compositions are provided. In particular, methods for preparing protected granules containing morphinans, and solid dosage form pharmaceutical compositions produced using the morphinan-protected granules are provided.
Priority Applications (16)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201180068100.2A CN103402499B (en) | 2010-12-21 | 2011-06-22 | Preparation comprises the method for the stable pharmaceutical composition as solid dosage form of morphinan |
US13/166,770 US8597681B2 (en) | 2009-12-22 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
AU2011345329A AU2011345329B2 (en) | 2010-12-21 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US13/995,810 US9198861B2 (en) | 2009-12-22 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
BR112013015622A BR112013015622A2 (en) | 2010-12-21 | 2011-06-22 | methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
CA2822553A CA2822553A1 (en) | 2010-12-21 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
EP11731589.5A EP2654727A1 (en) | 2010-12-21 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
RU2013132138/15A RU2013132138A (en) | 2010-12-21 | 2011-06-22 | METHODS FOR PRODUCING A STABILIZED SOLID DOSED FORM OF PHARMACEUTICAL COMPOSITIONS CONTAINING MORPHINANES |
JP2013546107A JP5897036B2 (en) | 2010-12-21 | 2011-06-22 | Method for producing a stable solid dosage form pharmaceutical composition comprising morphinan |
PCT/US2011/041533 WO2012087377A1 (en) | 2010-12-21 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
MX2013007057A MX2013007057A (en) | 2010-12-21 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans. |
KR1020137019037A KR101748906B1 (en) | 2010-12-21 | 2011-06-22 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
ZA2013/03988A ZA201303988B (en) | 2010-12-21 | 2013-05-31 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US14/092,375 US8980319B2 (en) | 2009-12-22 | 2013-11-27 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
JP2015154715A JP2015193668A (en) | 2010-12-21 | 2015-08-05 | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans |
US14/921,188 US20160184232A1 (en) | 2009-12-22 | 2015-10-23 | Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US28465109P | 2009-12-22 | 2009-12-22 | |
US61/284,651 | 2009-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2011087765A2 WO2011087765A2 (en) | 2011-07-21 |
WO2011087765A3 true WO2011087765A3 (en) | 2012-01-12 |
Family
ID=43498619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/061400 WO2011087765A2 (en) | 2009-12-22 | 2010-12-21 | Methods of producing stabilized solid pharmaceutical compositions containing morphinans |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2011087765A2 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9050335B1 (en) | 2011-05-17 | 2015-06-09 | Mallinckrodt Llc | Pharmaceutical compositions for extended release of oxycodone and acetaminophen resulting in a quick onset and prolonged period of analgesia |
US8858963B1 (en) | 2011-05-17 | 2014-10-14 | Mallinckrodt Llc | Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia |
US8741885B1 (en) | 2011-05-17 | 2014-06-03 | Mallinckrodt Llc | Gastric retentive extended release pharmaceutical compositions |
CN103432107A (en) * | 2013-08-20 | 2013-12-11 | 安徽省先锋制药有限公司 | Tapentadol hydrochloride paracetamol orally disintegrating tablet and preparation method thereof |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030182A1 (en) * | 2003-09-26 | 2005-04-07 | Alza Corporation | Controlled release formulations exhibiting an ascending rate of release |
US20070207200A1 (en) * | 2006-03-06 | 2007-09-06 | Pozen Inc. | Dosage forms for administering combinations of drugs |
WO2008015221A2 (en) * | 2006-08-04 | 2008-02-07 | Ethypharm | Multilayer orally disintegrating tablet |
WO2009114648A1 (en) * | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4851226A (en) | 1987-11-16 | 1989-07-25 | Mcneil Consumer Products Company | Chewable medicament tablet containing means for taste masking |
US5075114A (en) | 1990-05-23 | 1991-12-24 | Mcneil-Ppc, Inc. | Taste masking and sustained release coatings for pharmaceuticals |
CA2128820A1 (en) | 1993-07-27 | 1995-01-28 | Walter G. Gowan, Jr. | Rapidly disintegrating pharmaceutical dosage form and process for preparation thereof |
-
2010
- 2010-12-21 WO PCT/US2010/061400 patent/WO2011087765A2/en active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005030182A1 (en) * | 2003-09-26 | 2005-04-07 | Alza Corporation | Controlled release formulations exhibiting an ascending rate of release |
US20070207200A1 (en) * | 2006-03-06 | 2007-09-06 | Pozen Inc. | Dosage forms for administering combinations of drugs |
WO2008015221A2 (en) * | 2006-08-04 | 2008-02-07 | Ethypharm | Multilayer orally disintegrating tablet |
WO2009114648A1 (en) * | 2008-03-11 | 2009-09-17 | Depomed Inc. | Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic |
Non-Patent Citations (1)
Title |
---|
ALTAF S A ET AL: "BEAD COMPACTS. II. EVALUATION OF RAPIDLY DISINTEGRATING NONSEGREGATING COMPRESSED BEAD FORMULATIONS", DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, NEW YORK, NY, US, vol. 25, no. 5, 1 May 1999 (1999-05-01), pages 635 - 642, XP001070236, ISSN: 0363-9045, DOI: 10.1081/DDC-100102219 * |
Also Published As
Publication number | Publication date |
---|---|
WO2011087765A2 (en) | 2011-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013007057A (en) | Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans. | |
IL245050A0 (en) | Optimized fc variants, pharmaceutical compositions and medicaments comprising the same, and methods for their production | |
AP2012006135A0 (en) | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof. | |
IL208832A (en) | 3-aminocarbazole compounds, pharmaceutical compositions containing them, preparation methods thereof and use thereof in the production of drugs | |
WO2012024620A3 (en) | Autotaxin inhibitors and uses thereof | |
WO2008132229A3 (en) | Highly concentrated insulin solutions and compositions | |
WO2011060049A3 (en) | Spiro-oxindole mdm2 antagonists | |
EP2251038A4 (en) | Solid dispersion, pharmaceutical compositions containing the same, and processes for the production of both | |
EP2447253A4 (en) | Dihydropyrimidine compounds and preparation methods, pharmaceutical compositions and uses thereof | |
WO2010092090A3 (en) | Novel salts of sitagliptin | |
WO2008046581A3 (en) | Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments | |
WO2010117738A3 (en) | Solid state forms of sitagliptin salts | |
HK1164292A1 (en) | Novel tricyclic derivative or pharmaceutically acceptable salts thereof, preparation method thereof, and pharmaceutical composition containing the same | |
ZA201209739B (en) | Levocarrimycin,pharmaceutical compositions,preparation methods and uses thereof | |
WO2010151541A8 (en) | Polymorphic form d of bazedoxifene acetate and methods of preparing same | |
WO2012174158A3 (en) | Administration of benzodiazepine | |
ZA201301463B (en) | Pharmaceutical compositions for calonolides,their derivatives and analogues,and process for producing the same | |
WO2011104652A3 (en) | Veterinary compositions | |
WO2011009938A3 (en) | Stambomycin and derivatives, their production and their use as drugs | |
WO2009115084A3 (en) | Pyrrolopyrimidine derivatives, and use thereof | |
IL212942A (en) | Rifamycin derivatives, process for their preparation, pharmaceutical compositions comprising the same and uses thereof | |
IL207183A (en) | Dihydroindolone compounds, process for their preparation and pharmaceutical compositions containing them | |
EP2386553A4 (en) | Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses | |
EP2504331A4 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
IL213671A (en) | Pharmaceutical compositions comprising aleglitazar, process for their manufacture and use thereof in the preparation of medicaments |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10798238 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 10798238 Country of ref document: EP Kind code of ref document: A2 |